Article Text

Download PDFPDF

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Wu H, Chen Y, Wang Z, et al. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. J Immunother Cancer 2019;7:264. doi: 10.1186/s40425-019-0737-3

In the article titled ‘Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers’, there is the following errors:

In the abstract, the sentence ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p<0.001)’ should instead read ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p=0.003)’

Additionally, in Figure 6:

  1. Line 5, ‘HLA-DQA1’ should be ‘HLA-DQA2’

  2. Line 51–69 (from ENDRB to TIGIT), the category of these genes ‘Other’ should be ‘Receptor’

  3. Line 70–75 (from ARG1 to PRF1), the category of these genes ‘Receptor’ should be ‘Other’.

The correct Figure 6 can be seen below:

Embedded Image